TRANSGENE BIOTEK LTD. Share Price

Transgene Biotek Limited is an India-based biotechnology company. It is engaged in the research and development of vaccines, oncology, and new drug delivery technologies. Its portfolio of products includes oncology, autoimmunity, drug delivery and biogenetics. The Company offers TrabiAAV, which is a platform for the delivery of micro-ribonucleic acids (miRNAs), short hairpin RNA (ShRNAs), immunogens developing clinical significance in gene therapy and CRISPR/cas 9 technologies. Its monoclonal antibody therapy is the use of monoclonal antibodies to specifically bind to target cells. Its TrabiORAL drug is focused on delivering proteins and peptides orally for a variety of human diseases. Its TBL-1203 drug is used to strengthen cell-mediated immunity and complete the elimination of the human immunodeficiency virus (HIV), without any need for retroviral drug therapy. Its Tacrolimus drug suppresses the immune system and is mainly used to prevent rejection of transplanted organs.As of 25 May 2026, TRANSGENE BIOTEK LTD. share price is ₹3.13. The stock opened at ₹3.12, compared to its previous close of ₹3.06. During today's trading session, TRANSGENE BIOTEK LTD. share price moved in the range of ₹3.02 to ₹3.35, with an average price of ₹3.19 for the day. Looking at its last 52-week, the stock has touched a low of ₹3.02 and a high of ₹3.35.

The market capitalization of TRANSGENE BIOTEK LTD. is ₹23 Crs, with a P/E ratio of -12.2 and a dividend yield of 0.00%.